Genomic, Immunological, and Clinical Characterization of Pyroptosis in Ovarian Cancer

被引:7
作者
Zhou, Min [1 ]
Li, Bingshu [1 ]
Liu, Jianfeng [1 ]
Hong, Li [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Gynecol & Obstet, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China
关键词
pyroptosis; gynecological cancer; tumor microenvironment; immunotherapy; overall survival; TUMOR-INFILTRATING LYMPHOCYTES; FAVORABLE PROGNOSIS; EXPRESSION; MICROENVIRONMENT; PD-1/PD-L1; INHIBITORS; CD44;
D O I
10.2147/JIR.S344554
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: Pyroptosis is a form of lytic programmed cell death that is associated with the pathogenesis of many tumors. However, the potential roles of pyroptosis-related genes (PRGs) in the tumor microenvironment (TME) remain unclear. Materials and Methods: We systematically described the genetic and transcriptional alterations in PRGs in gynecological cancers. An unsupervised clustering method was used to investigate the molecular subtypes of ovarian cancer (OV) and systematically analyze the TME cell infiltration characteristics. A prognostic signature and nomogram were established to quantify the pyroptosis patterns of individual tumors. We also analyzed the expression levels of eight PRGs in the OV tissues. Results: Two distinct molecular subtypes of OV were identified, and these two distinct molecular subtypes could predict clinicopathological features, prognosis, TME stromal activity, immune infiltrating cells, and immune checkpoints. A prognostic signature was established, and its predictive capability was validated. Low risk score, characterized by activation of immunity, upregulation of programmed death-ligand 1 expression, lower tumor immune dysfunction and exclusion scores, lower tumor mutation burden, and favorable prognosis. These findings suggested that low-risk patients with OV may be more sensitive to immunotherapy. In addition, this signature could effectively predict the response to chemotherapy in patients with OV. Furthermore, a prognostic nomogram was generated, which exhibited superior predictive accuracy. Conclusion: This study highlights the crucial role of PRGs in the TME and may help develop immunotherapies and promote individualized therapeutic strategies for patients with OV.
引用
收藏
页码:7341 / 7358
页数:18
相关论文
共 48 条
  • [1] Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
    Ai, Luoyan
    Xu, Antao
    Xu, Jie
    [J]. REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY, 2020, 1248 : 33 - 59
  • [2] Targeting the microenvironment in solid tumors
    Belli, Carmen
    Trapani, Dario
    Viale, Giulia
    D'Amico, Paolo
    Duso, Bruno Achutti
    Della Vigna, Paolo
    Orsi, Franco
    Curigliano, Giuseppe
    [J]. CANCER TREATMENT REVIEWS, 2018, 65 : 22 - 32
  • [3] Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
    Boussios, Stergios
    Karihtala, Peeter
    Moschetta, Michele
    Karathanasi, Afroditi
    Sadauskaite, Agne
    Rassy, Elie
    Pavlidis, Nicholas
    [J]. DIAGNOSTICS, 2019, 9 (03)
  • [4] PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca"
    Boussios, Stergios
    Karathanasi, Afroditi
    Cooke, Deirdre
    Neille, Cherie
    Sadauskaite, Agne
    Moschetta, Michele
    Zakynthinakis-Kyriakou, Nikolaos
    Pavlidis, Nicholas
    [J]. DIAGNOSTICS, 2019, 9 (02)
  • [5] The Significance of VSIG4 Expression in Ovarian Cancer
    Byun, Jung Mi
    Jeong, Dae Hoon
    Choi, In Hak
    Lee, Dae Sim
    Kang, Mi Seon
    Jung, Keun Ok
    Jeon, You Kyung
    Kim, Young Nam
    Jung, Eun Jung
    Lee, Kyung Bok
    Sung, Moon Su
    Kim, Ki Tae
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (05) : 872 - 878
  • [6] New horizons in tumor microenvironment biology: challenges and opportunities
    Chen, Fei
    Zhuang, Xueqian
    Lin, Liangyu
    Yu, Pengfei
    Wang, Ying
    Shi, Yufang
    Hu, Guohong
    Sun, Yu
    [J]. BMC MEDICINE, 2015, 13
  • [7] Microcell-Mediated Chromosome Transfer Identifies EPB41L3 as a Functional Suppressor of Epithelial Ovarian Cancers
    Dafou, Dimitra
    Grun, Barbara
    Sinclair, John
    Lawrenson, Kate
    Benjamin, Elizabeth C.
    Hogdall, Estrid
    Kruger-Kjaer, Susanne
    Christensen, Lise
    Sowter, Heidi M.
    Al-Attar, Ahmed
    Edmondson, Richard
    Darby, Stephen
    Berchuck, Andrew
    Laird, Peter W.
    Pearce, C. Leigh
    Ramus, Susan J.
    Jacobs, Ian J.
    Gayther, Simon A.
    [J]. NEOPLASIA, 2010, 12 (07): : 579 - U83
  • [8] Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
    Erkes, Dan A.
    Cai, Weijia
    Sanchez, Ileine M.
    Purwin, Timothy J.
    Rogers, Corey
    Field, Conroy O.
    Berger, Adam C.
    Hartsough, Edward J.
    Rodeck, Ulrich
    Alnemri, Emad S.
    Aplin, Andrew E.
    [J]. CANCER DISCOVERY, 2020, 10 (02) : 254 - 269
  • [9] Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer
    Gao, Jianwei
    Qiu, Xiangyu
    Xi, Guangmin
    Liu, Hongbing
    Zhang, Fang
    Lv, Tangfeng
    Song, Yong
    [J]. ONCOLOGY REPORTS, 2018, 40 (04) : 1971 - 1984
  • [10] Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
    Garris, Christopher S.
    Luke, Jason J.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (15) : 3901 - 3907